Clinical Trial Update: ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) [Phase 2]

View source ↗

Summary

Phase 2 trial update for ADP-A2M4CD8 TCR therapy alone and in combination with nivolumab in HLA-A2+ MAGE-A4 positive ovarian cancer (SURPASS-3); study is active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ADP-A2M4CD8
• nivolumab (nivolumab)

Snippet

Sponsor: USWM CT, LLC | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING